Spevatamig (PT886)

PreclinicalSmall molecule

Spevatamig (PT886) is one of 18 small molecule programs targeting Gastric or Gastroesophageal Junction Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting

Gastric or Gastroesophageal Junction AdenocarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

17 competitors in Gastric or Gastroesophageal Junction Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

4 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 3

QLS31905

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 4

Tuoyi

CCoherus Oncology, Inc.

Phase 2

2 5

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 6

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 7

Taxol

Teva

Preclinical

1 8

Gemzar

Johnson & Johnson

Preclinical

1 9

Abraxane

Bristol-Myers Squibb

Preclinical

1 10

Keytruda

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05482893

Clinical

Trials by Indication[1]

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spevatamig (PT886). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spevatamig (PT886) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spevatamig (PT886). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phanes Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPhanes Therapeutics

Spevatamig (PT886)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News